丙戊酸镁缓释片联合奥氮平治疗脑外伤所致精神障碍的疗效及安全性观察

Observation on the effect and safety of Magnesium Valproate Sustained-Release Tablets and Olanzapine in mental disorder caused by brain injuries

目的探讨丙戊酸镁缓释片联合奥氮平对脑损伤所致精神障碍患者的临床疗效及安全性。方法将60例脑损伤所致精神障碍患者分为合用组和单用组各30例,合用组予丙戊酸镁缓释片合用奥氮平治疗,单用组单用奥氮平治疗,疗程均为8周。在治疗前和治疗后分别用阳性和阴性症状量表(PANSS)评定疗效,并观察两组的不良反应。以症状量表(TESS)评定其不良反应。结果治疗8周末,合用组总有效率为93.33%,单用组总有效率为76.27%,两组比较差异有统计学意义(χ2=3.27,P<0.05);治疗2周末起PANSS评分合用组较单用组下降更显著(t=7.83,P<0.01);两组TESS评分比较差异无统计学意义(t=1.74,P>0.05)。结论丙戊酸镁缓释片联合奥氮平片能显著提高脑外伤所致精神障碍患者临床疗效,安全性高,依从性好。

Objective To discuss the clinical effect and safety of Magnesium Valproate Sustained-Release Tablets and Olanzapine in the treatment of mental disorder caused by brain injuries. Methods Sixty cases of mental disorder caused by brain injuries were randomly divided into two groups,the combination group with Magnesium Valproate Sustained-Release Tablets combined with Olanzapine（n = 30） and the single group with Olanzapine（n = 30） for 8 weeks.Positive and Negative Syndrome Scale（PANSS） was used to assess efficacy.And side effects were evaluated by Treatment Emergent Side-effect Scale（TESS）. Results At the end of the 8 th week,the total effective rate of the combination group was 93.33%,and that of the single group was 76.27%（χ2 = 3.27,P 0.05）.PANSS in the combination group was significantly higher than that in the single group（t =7.83,P 0.01）.There was no significant difference between the two groups in TESS（t = 1.74,P 0.05）. Conclusions The therapy of Magnesium Valproate Sustained-Release Tablets and Olanzapine has advanced curative effect in the treatment of mental disorder caused by brain injuries,with high safety and good compliance.